Abstract
Osteoclasts are cells specialized in bone resorption. Currently, studies on murine osteoclasts are primarily performed on bone marrow-derived cells with the use of many animals and limited cells available. ER-Hoxb8 cells are conditionally immortalized monocyte/macrophage murine progenitor cells, recently described to be able to differentiate toward functional osteoclasts. Here, we produced an ER-Hoxb8 clonal cell line from C57BL/6 bone marrow cells that strongly resembles phenotype and function of the conventional bone marrow-derived osteoclasts. We then used CRISPR/Cas9 technology to specifically inactivate genes by biallelic mutation. The CRISPR/Cas9 system is an adaptive immune system in Bacteria and Archaea and uses small RNAs and Cas nucleases to degrade foreign nucleic acids. Through specific-guide RNAs, the nuclease Cas9 can be redirected toward any genomic location to genetically modify eukaryotic cells. We genetically modified ER-Hoxb8 cells with success, generating NFATc1(-/-) and DC-STAMP(-/-) ER-Hoxb8 cells that lack the ability to differentiate into osteoclasts or to fuse into multinucleated osteoclasts, respectively. In conclusion, this method represents a markedly easy highly specific and efficient system for generating potentially unlimited numbers of genetically modified osteoclast precursors.
Original language | English |
---|---|
Pages (from-to) | 957-966 |
Journal | Journal of Leukocyte Biology |
Volume | 101 |
Issue number | 4 |
Early online date | 5 Dec 2016 |
DOIs | |
Publication status | Published - Apr 2017 |
Bibliographical note
With supporting informationFunding
We gratefully acknowledge the financial support from 7th Framework Programme of the European Union, project Osteoimmune (Grant 289150), Dutch Arthritis Foundation (Reumafonds) (RF 11-1-305), and the American Lebanese Syrian Associated Charities (ALSAC).
Funders | Funder number |
---|---|
Dutch Arthritis Foundation | RF 11-1-305 |
Seventh Framework Programme | |
American Lebanese Syrian Associated Charities | |
European Commission | 289150 |